I Leclercq, A Saliez, P E Wallemacq, Y Horsmans, L Lambotte – 30 December 2003 – Although the monoethylglycinexylidide (MEGX) test defined as a single determination of MEGX plasma concentration after lidocaine injection has been proposed as a liver function test, some discrepancies appeared in assessing the quality of liver donor for transplantation as well as the severity of liver disease. The present study used a severe ischemia‐ reperfusion liver injury (IRI) in rat to evaluate the various factors able to influence the level of MEGX.

T Kitada, S Seki, K Nakatani, N Kawada, T Kuroki, T Monna – 30 December 2003 – C‐Myb is a sequence‐specific DNA binding protein that regulates the expression of genes involved in cell proliferation and differentiation. The present study was designed to elucidate the role of c‐Myb in the pathogenesis of chronic liver disease by an immunohistochemical approach. In normal (control) livers, few or no hepatic cells were positive for c‐Myb.

M Wettstein, D Haussinger – 30 December 2003 – Medium osmolarity sensitively regulates Kupffer cell functions like phagocytosis and prostaglandin (PG) and cytokine production. Betaine and taurine, recently identified as osmolytes in liver cells, interfere with these effects. Because Kupffer cell activation is an important pathogenic mechanism in ischemia‐reoxygenation injury, the influence of osmolarity and osmolytes was investigated in a rat liver perfusion model of warm ischemia.

M J Tong, L M Blatt, J G McHutchison, R L Co, A Conrad – 30 December 2003 – Patients with chronic hepatitis C (n = 103) were treated for 24 weeks with interferon alfa 2b and followed up for 24 weeks after cessation of therapy (week 48). When hepatitis C virus (HCV) RNA at week 48 was used to assess interferon response, 15 (14.6%) were virological complete responders, and all have remained HCV RNA negative for a mean of 3 years. At week 48, 3 of 15 virological complete responders had elevated alanine transaminase (ALT) values.

R P Perrillo – 30 December 2003 – This article reviews the ways in which liver biopsy provides a resource to the clinician when making management decisions for patients with chronic hepatitis C. Liver biopsy provides information about the extent and distribution of inflammation and allows grading and staging of the disease (the amount of fibrosis). Furthermore, the liver biopsy allows some assessment of the rate of disease progression whenever the date of onset of infection is known.

E B Keeffe, F B Hollinger – 30 December 2003 – Chronic hepatitis C is an insidious disease associated with significant morbidity and mortality. Currently, the only approved therapies for chronic hepatitis C are the α interferons. Consensus interferon (CIFN) is a nonnatural, synthetic, recombinant type I interferon derived by assigning the most commonly observed amino acid in each position of several α interferon nonallelic subtypes to generate a consensus sequence. The efficacy and safety of CIFN in the treatment of chronic hepatitis C were assessed in two large phase 3 trials.

Jane Collier, Jenny Heathcote – 30 December 2003

Motoko Sasaki, Yasuni Nakanuma, Young S. Kim – 30 December 2003 – Mucin plays an important role in the development of hepatoliths, which are formed within the intrahepatic large bile ducts. To date, eight apomucins, components of mucin, have been identified.

Masahiro Arai, Satoshi Mochida, Akihiko Ohno, Shin Arai, Kenji Fujiwara – 30 December 2003 – Gut‐derived substances can activate Kupffer cells to provoke hepatic necrosis after partial hepatectomy in rats. A similar situation may occur during orthotopic liver transplantation (OLT), as congestion in the intestinal wall, caused by portal vein occlusion, is inevitable during the operation. The contribution of such substances to liver injury following OLT was investigated in rats.

Toshiyuki Maruyama, Shoji Kuwata, Kazuhiko Koike, Shiro Iino, Kiyomi Yasuda, Hiroshi Yotsuyanagi, Kyoji Moriya, Hisato Maekawa, Haruki Yamada, Yoichi Shibata, David R. Milich – 30 December 2003 – Precore hepatitis B virus (HBV) mutants may gradually prevail during or after seroconversion (SC) from hepatitis B e antigen (HBeAg) to hepatitis B e antigen antibody (anti‐HBe) status in many chronic hepatitis B (CH‐B) patients.